St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, is the leader in quadripolar technology with the only cardiac resynchronization therapy (CRT) system approved in the U.S. New data presented at
Heart Rhythm 2014
, the Heart Rhythm Society’s Annual Scientific Sessions, demonstrates increased survival, improved clinical outcomes and better cost utilization with St. Jude Medical’s quadripolar technology. The large and growing body of clinical evidence combined with a strong product pipeline, including next-generation multi-point pacing (investigational device in the U.S.), makes
St. Jude Medical’s quadripolar system
the standard-of-care in improving the management of CRT.
For the first time, St. Jude Medical quadripolar leads were compared head-to-head with bipolar leads in a retrospective, observational study. Data from the study were presented at a featured poster session titled
Reduced Mortality with Quadripolar versus Bipolar Left Ventricular Leads in Cardiac Resynchronization Therapy
, by Dr. Mintu Turakhia. With more than 23,000 patients, one of the largest populations reviewed to date, this study of newly-implanted CRT-Ds with the St. Jude Medical quadripolar left ventricular (LV) pacing system was associated with increased patient survival compared to patients implanted with bipolar LV pacing systems.
“This comparative effectiveness study is an important advancement in our understanding of the real world impact of St. Jude Medical’s quadripolar technology,” said Dr. Mintu Turakhia, assistant professor of Medicine at Stanford University. “These data are the most compelling thus far as they demonstrate that the St. Jude Medical quadripolar lead is associated with a statistically significant improvement in survival.”
The study evaluated survival outcomes for CRT patients using the Quartet
quadripolar LV lead, which offers alternative pacing vectors not available with bipolar LV leads. Comparing survival rates for patients with a quadripolar vs. bipolar lead, the study compared patients with newly implanted cardiac resynchronization therapy defibrillator (CRT-D) systems receiving the two different types of CRT leads. Among the more than 23,000 patients identified through St. Jude Medical’s device registration records as receiving a new CRT-D system, the number of deaths per 100 patient years in patients with a quadripolar lead (5.84 deaths) is statistically significantly lower than that of the patients with a bipolar lead (7.14 deaths) with a highly significant p-value of 0.004. This demonstrated an 18.2 percent reduction in mortality with quadripolar leads compared to bipolar leads suggesting that patients with the quadripolar LV leads may receive more effective CRT therapy.
“St. Jude Medical has an unwavering commitment to investing in disruptive technologies that transform the treatment of expensive epidemic diseases such as heart failure. We developed and launched the first quadripolar system in 2009 to manage the dynamic challenges of heart failure,” said Eric S. Fain, M.D., group president of St. Jude Medical. “With more than five years of commercial experience, the St. Jude Medical quadripolar system is redefining the standard-of-care in resynchronization therapy for heart failure patients around the world, now including the important clinical outcomes measure of all-cause survival.”